Table 4. Publications reporting data on key patient and disease characteristics and TMB.
| Publication | Main findings relating to TMB and patient/disease characteristic | P Value |
|---|---|---|
| SMOKING | ||
| Kadara 2017 [57] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | .002 |
| Kim 2017 [58] | TMB was higher in patients with a history of smoking (101.5 mutations) vs no smoking history (63.0 mutations) | .43 |
| Mahadevan 2017 [36] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | .047 |
| Ono 2017 [60] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | .0001 |
| Owada 2017 [51] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | < .001 |
| Quek 2018 [61] | TMB was higher in patients with a history of smoking (11.6 mut/Mb) vs no smoking history (4.0 mut/Mb) | .00016 |
| Reck 2017 [62] | TMB was higher in patients with a history of smoking (199 mutations) vs no smoking history (60 mutations) | .004 |
| Rizvi 2015 [1] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | .08 |
| Schrock 2016 [63] | TMB was higher in patients with a history of smoking (10.4 mut/Mb) vs no smoking history (3.3 mut/Mb) | NR |
| Shim 2015 [64] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | < .0001 |
| Wang 2017 [42] | TMB was higher in patients with a history of smoking vs no smoking history (values NR) | .00087 |
| Xiao 2016 [43] | TMB was higher in patients with a history of smoking (3 mut/Mb) vs no smoking history (2 mut/Mb) | .00139 |
| Xiao 2017 [65] | TMB was higher in patients with a history of smoking (126 mutations) vs no smoking history (46 mutations) | .031 |
| Chae 2018 [56] | Patients with a history of smoking were more likely to have TMB-H than TMB-L (values NR) | < .001 |
| Davis 2017 [28] | Smoking was associated with higher TMB mutation (TMB-H: 18 patients with history of smoking vs 1 patient with no history; TMB-L: 38 patients with history of smoking vs 25 patient with no history) | .001 |
| Lizotte 2016 [59] | Spearman’s rho: 0.5297 | .0009 |
| HISTOLOGY | ||
| Isaka 2017 [66] | TMB higher in patients with SCC (5.6 mut/Mb) vs adenocarcinoma (1.6) | NR |
| Kojima 2017 [67] | TMB higher in patients with SCC (5.6 mut/Mb) vs adenocarcinoma (1.6) | NR |
| Ono 2017 [60] | TMB higher in patients with SCC vs adenocarcinoma (no values reported) | .069 |
| Owada 2017 [51] | TMB higher in patients with SCC vs adenocarcinoma (no values reported) | < .001 |
| Schrock 2017 [54] | TMB higher in patients with non-adenocarcinoma (9.9 mut/Mb) vs adenocarcinoma (6.8 mut/Mb) | .176 |
| SEX | ||
| Owada 2017 [51] | TMB higher in male patients vs female (values NR) | < .001 |
| Xiao 2016 [43] | TMB higher in male patients (3 mut/Mb) vs female (2 mut/Mb) | < .001 |
| Xiao 2017 [65] | TMB higher in male patients (92 mutations) vs female (34 mutations) | < .001 |
| CANCER STAGE | ||
| Choi 2017 [27] | No association of disease stage and TMB in patients with stage I–III cancer (values NR) | .95 |
| Kim 2018 [58] | TMB higher in patients with stage I–III cancer (104.4 mutations) vs stage IV (80.0 mutations) | .277 |
| Xiao 2016 [43] | No clear differences in TMB between patients with stage I (2 mutations), stage II (2 mutations), stage III (2 mutations) and stage IV (2 mutations) | NR |
| Xiao 2017 [65] | No clear differences in TMB between patients with stage I (39.5 mutations), stage II (74.5 mutations), stage III (59.0 mutations) and stage IV (50.5 mutations) | NR |
| AGE | ||
| Ono 2017 [60] | TMB higher in patients aged ≥ 70 years vs < 70 years (values NR) | .106 |
| Wang 2017 [42] | TMB higher in patients aged ≥ 65 years vs < 65 years (values NR) | .0208 |
| Xiao 2016 [43] | No difference in TMB in patients aged ≥ 65 years (2 mutations) vs <65 years (2 mutations) | .616 |
| Xiao 2017 [65] | TMB higher in patients aged ≥ 65 years (80.5 mutations) vs < 65 years (48 mutations) | .897 |
| Zhang 2016 [68] | Log-2 transformed effect estimates for age in patient subgroups: | |
| Adenocarcinoma TP53-positive: –0.023 | .007 | |
| Adenocarcinoma TP53-negative: 0.01 | .30 | |
| Squamous cell TP53-positive: –0.009 | .22 | |
| Squamous cell TP53-negative: –0.011 | .37 |
Abbreviations: mut/MB, mutations per DNA megabase; NR, not reported; SCC, squamous cell carcinoma; TMB, total mutational burden.